Pramlintide

Pramlintide is a synthetic analogue of amylin, a hormone released by pancreatic beta cells alongside insulin. It was developed to restore part of the meal-related regulation lost when amylin secretion is deficient. The approved medicine, Symlin, supports glucose control in selected people with type 1 or type 2 diabetes who use mealtime insulin. Trials also examined weight reduction in obesity, providing an early clinical foundation for the newer amylin analogues now under investigation.

Overview

Molecular profile

Type: Synthetic amylin analogue; 37 amino acids Source
Chemical form: Pramlintide acetate in the approved Symlin product Source
Peptide-component formula: C171H267N51O53S2 Source
Peptide-component molecular weight: 3949.4 g/mol; acetate content is additional and variable Source
Acetate formula context: C171H267N51O53S2 · x C2H4O2, where 3 ≤ x ≤ 8 Source
Structural changes: Proline substitutions at human-amylin positions 25, 28 and 29; C-terminal amide and disulfide linkage Source
Receptor family: Amylin receptors formed from calcitonin receptor and RAMP accessory proteins Source

Forms and derivatives

Pramlintide acetate (Symlin)

The approved product uses pramlintide acetate. The peptide mass is 3949.4 g/mol, while the label allows variable acetate content in the salt formula.

Des-Lys1 pramlintide

The product label identifies the 2–37 fragment as a metabolite with biological activity in vitro.

Amylin helps regulate how quickly meal nutrients reach the circulation, how much glucagon the pancreas releases after eating, and the signals that influence food intake. Pramlintide has 37 amino acids and three proline substitutions relative to human amylin. Its approved formulation is pramlintide acetate. Section 11 of the FDA Symlin label describes the peptide and salt composition. The quoted molecular weight of 3,949.4 describes the peptide component; variable acetate content needs its own formula context.

This is a short-acting amylin analogue whose principal clinical studies used a defined pharmaceutical product with insulin. Long-acting analogues such as cagrilintide, petrelintide and eloralintide have different modifications and development programmes. Their results help extend amylin research, while pramlintide's own trials retain a specific role in explaining meal glucose and early obesity findings.

Uses and research areas

The currently listed Symlin prescribing information, updated December 2019 and rechecked in October 2026, indicates pramlintide for patients with type 1 or type 2 diabetes who use mealtime insulin and have not reached desired glucose control despite optimal insulin therapy. It serves as an adjunct in a treatment setting that requires coordinated monitoring of glucose and insulin-related risk.

The diabetes trials measured HbA1c, meal-related glucose excursions, weight and hypoglycemia. Obesity studies subsequently measured weight loss with pramlintide alone or alongside structured lifestyle support. The current US indication remains insulin-treated diabetes; the obesity trials describe a research programme and the rationale for developing longer-acting amylin medicines.

Mechanism of action

Insulin and amylin address complementary parts of a meal response. Insulin promotes glucose disposal and suppresses liver glucose production. Amylin slows gastric emptying, reduces the post-meal rise in glucagon and promotes fullness. Pramlintide reproduces these amylin-related effects, limiting the speed at which meal-derived glucose appears in blood. Section 12.1 of the FDA Symlin label explains this physiological combination.

An amylin receptor contains a calcitonin receptor associated with a receptor activity-modifying protein, or RAMP. The accessory protein changes how the receptor recognizes and responds to peptides. In Christopoulos and colleagues' cell experiments (1999), adding RAMP1 or RAMP3 to a human calcitonin-receptor construct generated amylin-binding receptor phenotypes. This provides the molecular basis for understanding the amylin receptor family. It also explains why receptor-component experiments and a clinical pramlintide trial address different levels of the biology.

Slowing glucose appearance becomes especially consequential when insulin is already present. A mismatch between insulin action and the available glucose can produce hypoglycemia. That connection is central to pramlintide's safety profile and to the way its clinical trials coordinated insulin treatment. It also shows why lower post-meal glucose and lower HbA1c need separate measurements: smoothing a meal excursion may add benefit even when average glucose improves similarly in both randomized groups.

Pharmacokinetics

Pramlintide has much shorter circulating persistence than the fatty-acid-modified GLP-1 and newer amylin analogues. The FDA Symlin label, section 12.3 reports about 30–40% absolute bioavailability after subcutaneous administration and an approximate 48-minute elimination half-life in healthy people. Its tabulated single-exposure studies reached maximum concentrations around 19–21 minutes, with half-life estimates of 48–55 minutes across the tested cohorts. The timing distinguishes rapid entry into circulation from the subsequent fall in the parent peptide.

Pramlintide: normalized parent-peptide elimination

Population: Healthy human participants in subcutaneous Symlin pharmacokinetic characterization. Administration: subcutaneous administration; illustration begins in the post-absorption elimination phase. Analyte: circulating pramlintide parent peptide.

The Symlin label reports an approximate human elimination half-life of 48 minutes. This calculated curve shows the original pramlintide peptide repeatedly halving at that rate after absorption, starting from an arbitrary 100%. It is an illustration rather than a measured patient concentration curve. The curve applies C/C0 = 2^(-t/t_half) with constant first-order elimination and reaches 50% after 48 minutes by construction. It models the parent peptide only; the absorption phase, repeated administration and the metabolite with activity in vitro are excluded. Parent disappearance does not specify the duration of the entire pharmacological response.

AstraZeneca; US Food and Drug Administration. SYMLIN (pramlintide acetate) injection: approved prescribing information. 2015. NDA 021332 supplement 025. SYMLIN FDA label section 12.3, Table 5 and Metabolism and Elimination: approximate 48-minute half-life in healthy individuals.

The elimination illustration uses the label's approximate 48-minute value in healthy participants. It begins after absorption at an arbitrary normalized concentration and includes only parent-peptide disappearance. The label also identifies a metabolite with biological activity in vitro, so the parent concentration alone cannot specify the entire duration of pharmacological action. The graph leaves absorption and metabolite effects unmodeled.

Research findings

Adjunct treatment in type 1 and type 2 diabetes

Ratner and colleagues (2004) randomized 651 people with type 1 diabetes in a one-year trial. Selected pramlintide groups had HbA1c reductions of 0.29 and 0.34 percentage points, compared with 0.04 with placebo. Their weight fell by about 0.4 kg while the placebo group gained 0.8 kg. The average HbA1c effect was modest, alongside a favorable weight direction. It describes an adjunct to ongoing insulin therapy in participants whose mean starting HbA1c was 8.9%.

In the corresponding type 2 diabetes trial, Hollander and colleagues (2003) enrolled 656 insulin-treated participants with a mean baseline HbA1c of 9.1%. One active group had a 0.62-percentage-point HbA1c decrease at 52 weeks, significantly greater than placebo, and a weight change of −1.4 kg versus +0.7 kg. The reported overall severe-hypoglycemia event rate did not increase. Background therapy sometimes included metformin or a sulfonylurea. The result therefore belongs to insulin-treated type 2 diabetes with that treatment context.

Edelman and colleagues (2006) studied 296 people with type 1 diabetes using intensive insulin therapy over 29 weeks. HbA1c decreased by approximately 0.5 percentage points in both groups. With pramlintide, blood glucose rose less after meals, and weight fell by 1.3 kg compared with a 1.2-kg gain with placebo. Severe hypoglycemia was more frequent with pramlintide. These findings show why HbA1c alone gives an incomplete picture: average glucose improved similarly, while post-meal glucose, weight and low-glucose risks differed.

Obesity studies and their follow-up populations

Aronne and colleagues (2007) conducted a 16-week trial in 204 adults with obesity who were not using insulin. Among participants who completed the trial, the placebo-corrected weight reduction was 3.7%, or 3.6 kg. Withdrawal occurred in 29% of the active group and 25% of the placebo group. A completer result describes the retained participants, and the withdrawal proportions show how much of the original randomized population it leaves outside that estimate.

Smith and colleagues (2008) randomized 411 adults with obesity to pramlintide or placebo alongside structured lifestyle intervention. In the four-month evaluable population of 270, mean losses across active groups ranged from 3.8 to 6.1 kg versus 2.8 kg with placebo. A selected single-blind extension continued for another eight months. In its one-year evaluable population of 146, most active groups maintained their initial losses while placebo regained weight; one active group did not maintain the loss. The changing analysis populations are essential to understanding the apparent durability.

These obesity trials demonstrated that an amylin analogue could influence human weight alongside its meal-glucose effects. They also exposed challenges of treatment persistence and longer-term evaluation. Later amylin programmes developed molecules with longer circulating exposure and new clinical trial designs, building on this biological rationale while testing their own preparations.

Safety and tolerability

The Symlin label carries a boxed warning for severe hypoglycemia when used with insulin, especially in type 1 diabetes. Episodes can occur after meals and can impair judgment or consciousness. Careful patient selection, glucose monitoring and coordinated insulin management are part of its clinical use. This risk follows from the interaction between insulin action and pramlintide's slowing of nutrient appearance.

Nausea, vomiting, reduced appetite and headache occur in clinical use. Contraindications include hypoglycemia unawareness, confirmed gastroparesis and serious hypersensitivity. Slower gastric emptying can also alter the timing of oral-drug absorption, and the label cautions against combining medicines that further change gastrointestinal motility. Safety estimates from diabetes trials belong to supervised adjunct treatment with a specified product and background insulin regimen.

What the research means

Pramlintide established a clinical role for replacing amylin-related signaling alongside insulin. Its randomized trials show that post-meal glucose, HbA1c and weight can respond differently, and that those benefits must be considered together with hypoglycemia. That makes it a useful example of complementary hormones: adding a second physiological signal changes both the glucose profile and the demands of coordinated treatment.

The obesity results helped justify continued development of amylin analogues. Their interpretation depends on who remained in the study and whether the longer follow-up preserved randomization and blinding. Pramlintide's relatively short persistence is also a substantial difference from contemporary long-acting candidates. The older trials provide human proof of biological activity, while each newer molecule needs evidence for its own exposure, tolerability and clinical outcomes.

FAQs

What does pramlintide add to insulin treatment?

It provides an amylin-related signal that slows nutrient appearance, suppresses post-meal glucagon and influences fullness. Its trials measured meal-glucose patterns, HbA1c and weight alongside insulin. The interaction also raises hypoglycemia risk, making coordinated clinical management part of the approved adjunct use.

Why can meal glucose improve when HbA1c changes similarly in both groups?

HbA1c averages glucose over months and can conceal differences around meals. In the intensive-insulin trial, both groups improved HbA1c while pramlintide improved post-meal excursions and weight. Severe hypoglycemia rates also increased, so the meal profile and safety result are needed together. Edelman and colleagues (2006) report the study.

How strong is the obesity evidence for pramlintide?

Short randomized trials found weight reduction, and a selected extension suggested maintenance in most active groups. Completer and evaluable populations became smaller than the original randomized cohorts. Those population changes affect the size and durability of the reported result; obesity is not the current US approved indication.

How does pramlintide relate to the longer-acting amylin candidates?

Pramlintide has short human circulating persistence and established insulin-adjunct evidence. Cagrilintide, petrelintide and eloralintide use different molecular designs and clinical programmes. The early pramlintide obesity studies supplied a biological foundation, while the newer preparations require their own clinical assessment.

Cagrilintide, petrelintide and eloralintide extend the amylin strategy through different molecular designs. CagriSema adds GLP-1 receptor activity by coadministering semaglutide with cagrilintide. Semaglutide and tirzepatide offer useful comparison with incretin pathways, whose glucose-dependent pancreatic actions differ from pramlintide's principal role in regulating the meal response.

References

AstraZeneca. SYMLIN (pramlintide acetate) injection: US prescribing information. DailyMed listing updated December 18, 2019; checked October 13, 2026.
The current listing defines adjunct use with mealtime insulin, severe hypoglycemia precautions and contraindications involving gastric emptying and hypoglycemia awareness.
AstraZeneca; US Food and Drug Administration. SYMLIN (pramlintide acetate) injection: approved prescribing information. 2015. NDA 021332 supplement 025.
The FDA label separates the peptide's mass from variable acetate content and supplies the human single-exposure pharmacokinetic table.
Christopoulos G, Perry KJ, Morfis M, et al. (1999). Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Molecular Pharmacology 56(1):235–242. DOI: 10.1124/mol.56.1.235.
Cell coexpression experiments establish how calcitonin receptor and accessory RAMP proteins generate amylin receptor phenotypes.
Ratner RE, Dickey R, Fineman M, et al. (2004). Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabetic medicine : a journal of the British Diabetic Association 21(11):1204–1212. DOI: 10.1111/j.1464-5491.2004.01319.x.
The one-year type 1 diabetes trial quantifies modest HbA1c improvement and weight effects of pramlintide added to insulin.
Hollander PA, Levy P, Fineman MS, et al. (2003). Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes care 26(3):784–790. DOI: 10.2337/diacare.26.3.784.
The one-year insulin-treated type 2 diabetes trial measures HbA1c and weight, with background diabetes medicines identified.
Edelman S, Garg S, Frias J, et al. (2006). A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes care 29(10):2189–2195. DOI: 10.2337/dc06-0042.
The intensive-insulin trial separates similar HbA1c changes from improved meal excursions, lower weight and higher severe-hypoglycemia event rates.
Aronne L, Fujioka K, Aroda V, et al. (2007). Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. The Journal of clinical endocrinology and metabolism 92(8):2977–2983. DOI: 10.1210/jc.2006-2003.
The short obesity study reports a completer weight effect and the withdrawal proportions needed to interpret that estimate.
Smith SR, Aronne LJ, Burns CM, et al. (2008). Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes care 31(9):1816–1823. DOI: 10.2337/dc08-0029.
The lifestyle-supported obesity study distinguishes four-month evaluable results from the smaller selected one-year extension population.
Cao J, Belousoff MJ, Liang YL, Johnson RM, Josephs TM, Fletcher MM, Christopoulos A, Hay DL, Danev R, Wootten D, Sexton PM. A structural basis for amylin receptor phenotype. Science. 2022;375(6587):eabm9609. DOI: 10.1126/science.abm9609.
Examines the receptor structures that explain how calcitonin receptor and RAMP partners produce amylin receptor phenotypes.

Glossary

Amylin: A pancreatic hormone released with insulin that helps regulate meal-related nutrient appearance, glucagon and fullness.
RAMP: Receptor activity-modifying protein: an accessory protein that changes the properties of a peptide receptor.
Gastric emptying: Movement of stomach contents into the intestine, where nutrients can be absorbed.
Glucagon: A pancreatic hormone that promotes glucose release from the liver.
HbA1c: Glycated hemoglobin, a marker of average blood glucose over the preceding months.
Hypoglycemia unawareness: Reduced ability to recognize warning symptoms as blood glucose falls.
Completer analysis: An analysis limited to people who finished the study, which can differ from an estimate for everyone randomized.
Elimination half-life: The time associated with a halving of parent-drug concentration during a characterized elimination phase.